Quick Answer
Breast cancer risk with menopause hormone therapy depends on the type of therapy, your age, how long you use it and your personal risk factors. In long-term results from the Women’s Health Initiative, estrogen alone was linked with fewer breast cancers, while estrogen plus a progestin was linked with more. For most healthy women under 60 or within 10 years of menopause, experts say the benefits of treating symptoms likely outweigh the risks. People with a history of breast cancer need a more careful, individual discussion.
Who this is for: women considering or using menopause hormone therapy who want a clear picture of breast cancer risk
What the Women's Health Initiative Found
The Women’s Health Initiative (WHI) included two large randomized trials that began in the 1990s with women ages 50 to 79. Women with a uterus took estrogen plus a progestin or a placebo, and women who had had a hysterectomy took estrogen alone or a placebo.[1]
In 2002, early results linked the estrogen-plus-progestin therapy to more breast cancers. The news led many women to stop hormone therapy.
The WHI tested one specific estrogen (conjugated equine estrogens) and one progestin (medroxyprogesterone acetate). Results may not apply in the same way to other products, such as estradiol or micronized progesterone, which are still being studied.
What Longer Follow-Up Showed
Researchers kept following WHI participants for about 20 years. Estrogen alone was linked with a lower rate of breast cancer and fewer breast cancer deaths compared with placebo. Estrogen plus a progestin was linked with a higher rate of breast cancer, but not a significant difference in breast cancer deaths.[1]
Later analyses also looked at age. Many WHI participants were in their 60s or 70s when they started, which is older than most women who begin therapy for symptoms today.
Staying active and keeping up with screenings are part of breast health at any age.
Estrogen Alone vs. Estrogen Plus Progestogen
Women who still have a uterus need a progestogen along with estrogen, because estrogen alone can thicken the uterine lining and raise the risk of endometrial cancer. Women who have had a hysterectomy can usually take estrogen alone.
In the WHI, the higher breast cancer rate was seen with the combination, not with estrogen alone. This suggests the progestogen part plays a role in breast cancer risk, although researchers are still learning how different progestogens compare.
Timing, Age and Duration
The Menopause Society states that for most healthy women with symptoms who are under 60 or within 10 years of menopause, the benefits of hormone therapy likely outweigh the risks.[2] It also notes that breast cancer risk does not rise appreciably with short-term use of estrogen plus progestogen, while observational studies suggest a rare increase with longer use.[2]
Your own risk also depends on factors like family history, breast density, alcohol use and weight. For more on how long to stay on therapy, see How Long Should You Stay on Menopause Hormone Therapy?
Vaginal Estrogen and Breast Cancer History
Low-dose vaginal estrogen uses very small amounts of hormone to treat dryness, painful sex and some urinary symptoms. For some breast cancer survivors whose symptoms do not improve with nonhormonal treatments, The Menopause Society says low-dose vaginal estrogen appears safe based on observational data.[2]
Systemic hormone therapy (pills, patches, gels or sprays) is generally not recommended for people who have had breast cancer. If you have a breast cancer history, any hormone decision should include your oncologist.
What Changed With FDA Labels in 2025 and 2026
On November 10, 2025, the FDA announced it would remove language about cardiovascular disease, breast cancer and probable dementia from the boxed warning on menopause hormone therapy products. The boxed warning about endometrial cancer remains for systemic estrogen-alone products.[3]
On February 12, 2026, the FDA approved the first updated labels for six products. Three more followed on October 30, 2026, and others are still under review.[4] The change reflects a fresh look at the research, not a finding that hormone therapy is risk-free. Breast cancer risk is still part of an informed decision.
How We Approach Hormone Therapy Safety at Lake Forest Regenesis
Allana reviews your symptoms, personal and family history, mammogram history, medications and other risk factors before discussing hormone therapy. She explains how the type, dose and length of therapy may affect your risk. For people with a breast cancer history or a strong family history, she coordinates with oncology or other specialists.
When to See a Provider
Call 911 for chest pain, sudden shortness of breath, sudden numbness or weakness, or trouble speaking. Contact a provider promptly for a new breast lump, skin dimpling, nipple changes or discharge, pain or swelling in one leg, or vaginal bleeding after menopause. Book a visit if you are considering hormone therapy, have questions about your current therapy, or have a personal or family history of breast cancer.
Related Service
Have questions about hormone therapy and your breast health? Allana can review your history and risk factors and help you weigh the options.
Frequently Asked Questions
Should I keep getting mammograms while on hormone therapy?
Yes. Keep following your recommended screening schedule. Hormone therapy can make breast tissue denser for some women, which can make mammograms a little harder to read.
Does a family history of breast cancer rule out hormone therapy?
Not always. It depends on who was affected, at what age and your other risk factors. Some people benefit from genetic counseling before deciding.
Do bioidentical hormones avoid breast cancer risk?
That has not been shown in large studies. The same general cautions apply to estrogen and progestogen products whatever their source.
If I stop hormone therapy, does the added risk go away?
Research suggests the added risk linked to estrogen plus progestogen tends to decline after stopping, though some studies suggest a small increase may last for years.
References
- Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020. Read the study
- The Menopause Society. The 2022 hormone therapy position statement (press release). Read the guidance
- U.S. Department of Health and Human Services. Fact sheet: FDA initiates removal of black box warnings from menopausal hormone replacement therapy products. 2025. Read the fact sheet
- U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. 2026. Read the article
This article is for general education and is not a substitute for individual medical advice. See our medical disclaimer.
